Your browser doesn't support javascript.
loading
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Veeranki, Omkara Lakshmi; Tong, Zhimin; Dokey, Rashmi; Mejia, Alicia; Zhang, Jianhu; Qiao, Yawei; Singh, Pankaj Kumar; Katkhuda, Riham; Mino, Barbara; Tailor, Ramesh; Canales, Jaime Rodriguez; Bassett, Roland; Ajani, Jaffer; Wu, Ji Yuan; Kopetz, Scott; Blum, Mariela; Hofstetter, Wayne; Tetzlaff, Michael; Krishnan, Sunil; Lin, Steven H; Maru, Dipen.
Afiliación
  • Veeranki OL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tong Z; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Dokey R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mejia A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Zhang J; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Qiao Y; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Singh PK; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Katkhuda R; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mino B; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tailor R; Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Canales JR; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bassett R; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ajani J; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wu JY; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kopetz S; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Blum M; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hofstetter W; Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tetzlaff M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Krishnan S; Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lin SH; Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Maru D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncotarget ; 10(45): 4703-4718, 2019 Jul 23.
Article en En | MEDLINE | ID: mdl-31384397
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos